hC Bioscience, Inc.
- Biotech or pharma, therapeutic R&D
Seeking partners to develop engineered tRNAs to cure genetic rare diseases caused by nonsense mutations. Our flagship asset, HCB-101, is expected to be in the clinic by 2H25. Clinical POC will open door to all liver-based diseases.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}